Otsuka's Voyxact slows kidney function loss in IgA nephropathy trial but falls short of expected benefit

STAT News reported on 4 June 2026 that Otsuka's kidney drug Voyxact (formally a late-stage investigational agent) demonstrated a statistically measurable slowing of kidney function loss at one year in patients with IgA nephropathy (IgAN), a chronic autoimmune condition in which immune complexes deposit in the kidney. However, the degree of benefit was described as less than expected based on earlier trial signals.

IgA nephropathy has a recognised genetic component, with genome-wide association studies having identified risk loci across populations; it is also notable for pronounced variation in disease course, with some patients progressing to end-stage kidney disease and others maintaining stable function for decades. The genetic architecture underlying this variability remains an active area of research.

The trial result is relevant to nephrologists, genetic researchers working on immune-mediated renal disease, and those tracking pharmacological approaches to conditions with complex genetic risk profiles. The drug has not yet received regulatory approval; the trial data are described as late-stage rather than registrational in the STAT News report.